Elicio Therapeutics, Inc. (ELTX) 10-Year Financial Performance & Capital Metrics

ELTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutElicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.Show more

Revenue $0
EBITDA -$44M -26.7%
Net Income -$52M -47.5%
EPS (Diluted) -4.25 +38.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -170157.38% -48943.2%
ROIC -2692.7% -602.8%
Debt/Equity -
Interest Coverage -98.87 -192.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM2.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.19%

ROCE

10Y Avg-328.74%

5Y Avg-209.92%

3Y Avg-175.56%

Latest-264.27%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2012	Dec 2013	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.3M	6.58M	4.03M	1.49M	2.88M	28.31M	0	0	0
Revenue Growth %	-	-0.1%	-0.39%	-0.63%	0.94%	8.83%	-1%	-	-
Cost of Goods Sold+	3.67M	3.17M	380K	1.14M	1.82M	1.23M	1.06M	1.17M	1.18M
COGS % of Revenue	0.5%	0.48%	0.09%	0.76%	0.63%	0.04%	-	-	-
Gross Profit+	3.62M	3.41M	3.65M	351K	1.06M	27.08M	-1.06M	-1.17M	-1.18M
Gross Margin %	0.5%	0.52%	0.91%	0.24%	0.37%	0.96%	-	-	-
Gross Profit Growth %	-	-0.06%	0.07%	-0.9%	2.03%	24.5%	-1.04%	-0.11%	-0.01%
Operating Expenses+	4.04M	3.81M	17.99M	38.94M	56.34M	66.39M	22.68M	34.58M	43.81M
OpEx % of Revenue	0.55%	0.58%	4.47%	26.19%	19.56%	2.34%	-	-	-
Selling, General & Admin	4.04M	3.61M	8.84M	9.15M	17.46M	17.78M	5.63M	11.9M	11.33M
SG&A % of Revenue	0.55%	0.55%	2.19%	6.16%	6.06%	0.63%	-	-	-
Research & Development	0	196.01K	9.15M	29.79M	38.88M	48.61M	17.05M	22.68M	33.66M
R&D % of Revenue	-	0.03%	2.27%	20.03%	13.5%	1.72%	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	-1.18M
Operating Income+	-419.22K	-397.8K	-14.34M	-38.59M	-55.27M	-39.31M	-23.73M	-35.74M	-44.99M
Operating Margin %	-0.06%	-0.06%	-3.56%	-25.95%	-19.19%	-1.39%	-	-	-
Operating Income Growth %	-	0.05%	-35.05%	-1.69%	-0.43%	0.29%	0.4%	-0.51%	-0.26%
EBITDA+	44K	62.54K	-14.34M	-38.09M	-54.65M	-38.51M	-22.68M	-34.58M	-43.81M
EBITDA Margin %	0.01%	0.01%	-3.56%	-25.62%	-18.97%	-1.36%	-	-	-
EBITDA Growth %	-	0.42%	-230.28%	-1.66%	-0.43%	0.3%	0.41%	-0.52%	-0.27%
D&A (Non-Cash Add-back)	463.22K	460.34K	2K	496K	628K	801K	1.06M	1.17M	1.18M
EBIT	1.5M	2.03M	-20.02M	-40.66M	-71.26M	-52.73M	-24.61M	-34.14M	-51.44M
Net Interest Income+	0	0	0	81.48K	-8.85M	-873.05K	-3.53M	-686K	322K
Interest Income	0	0	252K	81.48K	0	3.39K	64.83K	373K	777K
Interest Expense	307.45K	300.43K	0	0	8.85M	876.44K	3.6M	1.06M	455K
Other Income/Expense	1.61M	2.13M	-5.68M	-2.07M	-24.83M	-15.27M	-4.47M	550K	-6.91M
Pretax Income+	1.19M	1.73M	-20.02M	-40.66M	-80.11M	-54.57M	-28.21M	-35.2M	-51.9M
Pretax Margin %	0.16%	0.26%	-4.97%	-27.34%	-27.81%	-1.93%	-	-	-
Income Tax+	201.86K	452.78K	0	0	0	0	0	0	0
Effective Tax Rate %	0.26%	0.36%	1%	1%	1%	0.48%	1%	1%	1%
Net Income+	307.3K	632.24K	-20.02M	-40.66M	-80.11M	-26.4M	-28.21M	-35.2M	-51.9M
Net Margin %	0.04%	0.1%	-4.97%	-27.34%	-27.81%	-0.93%	-	-	-
Net Income Growth %	-	1.06%	-32.67%	-1.03%	-0.97%	0.67%	-0.07%	-0.25%	-0.47%
Net Income (Continuing)	992.12K	1.28M	-20.02M	-40.66M	-80.11M	-54.57M	-28.21M	-35.2M	-51.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	2.53M	2.12M	0	0	0	0	0	0	0
EPS (Diluted)+	50.21	103.31	-6.79	-1.50	-1.93	-19.32	-9.10	-6.96	-4.25
EPS Growth %	-	1.06%	-1.07%	0.78%	-0.29%	-9.01%	0.53%	0.24%	0.39%
EPS (Basic)	50.21	103.31	-6.79	-1.50	-1.93	-19.32	-9.10	-6.96	-4.25
Diluted Shares Outstanding	6.12K	6.12K	2.95M	8.15M	8.15M	3.2M	3.1M	5.06M	12.2M
Basic Shares Outstanding	6.12K	6.12K	2.95M	8.15M	8.15M	3.2M	3.1M	5.06M	12.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2012	Dec 2013	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.06M	2.62M	25.68M	6.11M	40.32M	91.25M	10.72M	16.35M	20.69M
Cash & Short-Term Investments	1.4M	2.06M	25.51M	5.57M	34.61M	88.76M	7.8M	12.89M	17.62M
Cash Only	1.4M	2.06M	25.51M	5.57M	34.61M	88.76M	7.8M	12.89M	17.62M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	580.38K	485.76K	107K	440K	5M	806K	0	0	0
Days Sales Outstanding	29.03	26.94	9.69	108	633.68	10.39	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	60K	95K	360K	379K	36K	895K	1.28M
Total Non-Current Assets+	8.97M	8.44M	949K	5.78M	7.03M	5.27M	11.95M	10.8M	7.49M
Property, Plant & Equipment	6.61M	6.17M	17K	4.78M	4.23M	4.44M	8.5M	7.28M	6.19M
Fixed Asset Turnover	1.10x	1.07x	237.00x	0.31x	0.68x	6.38x	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	1.63M	1.67M	932K	999K	822K	723K	617K	0	696K
Other Non-Current Assets	734.38K	598.84K	0	0	1.98M	106K	2.83M	3.52M	600K
Total Assets+	11.03M	11.06M	26.63M	11.89M	47.35M	96.51M	22.66M	27.15M	28.18M
Asset Turnover	0.66x	0.59x	0.15x	0.13x	0.06x	0.29x	-	-	-
Asset Growth %	-	0%	1.41%	-0.55%	2.98%	1.04%	-0.77%	0.2%	0.04%
Total Current Liabilities+	1.1M	1.15M	7.36M	26.57M	107.45M	11.3M	6.87M	9.76M	11.52M
Accounts Payable	209.52K	37.62K	534K	11.24M	5.58M	4.71M	2.81M	4.37M	1.04M
Days Payables Outstanding	20.82	4.33	512.92	3.61K	1.12K	1.39K	968.61	1.36K	321.62
Short-Term Debt	115.58K	122.18K	0	6.88M	80.56M	952K	692K	0	901K
Deferred Revenue (Current)	91K	82K	19K	0	1000K	1000K	1000K	0	1000K
Other Current Liabilities	688.33K	905.11K	6.8M	6.35M	14.21M	3.33M	444K	2.57M	2.31M
Current Ratio	1.87x	2.28x	3.49x	0.23x	0.38x	8.08x	1.56x	1.68x	1.80x
Quick Ratio	1.87x	2.28x	3.49x	0.23x	0.38x	8.08x	1.56x	1.68x	1.80x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.69M	5.46M	362K	3.9M	30.35M	3.71M	6.88M	6.02M	27.97M
Long-Term Debt	5.32M	5.2M	0	0	635K	0	0	0	20.03M
Capital Lease Obligations	0	0	0	3.9M	3.85M	3.71M	6.79M	6.01M	5.11M
Deferred Tax Liabilities	113K	4K	0	0	0	0	0	0	0
Other Non-Current Liabilities	250K	250K	0	0	0	0	92K	11K	2.83M
Total Liabilities	6.79M	6.6M	7.72M	30.47M	137.8M	15.01M	13.75M	15.77M	39.49M
Total Debt+	5.44M	5.32M	0	10.78M	85.04M	4.66M	7.48M	6.92M	26.04M
Net Debt	4.04M	3.27M	-25.51M	5.21M	50.44M	-84.09M	-316K	-5.98M	8.42M
Debt / Equity	1.28x	1.19x	-	-	-	0.06x	0.84x	0.61x	-
Debt / EBITDA	123.65x	85.13x	-	-	-	-	-	-	-
Net Debt / EBITDA	91.73x	52.24x	-	-	-	-	-	-	-
Interest Coverage	-1.36x	-1.32x	-	-	-6.25x	-44.85x	-6.60x	-33.75x	-98.87x
Total Equity+	4.24M	4.46M	18.91M	-18.59M	-90.45M	81.51M	8.91M	11.37M	-11.31M
Equity Growth %	-	0.05%	3.24%	-1.98%	-3.87%	1.9%	-0.89%	0.28%	-1.99%
Book Value per Share	692.52	728.69	6.41	-2.28	-11.10	25.47	2.88	2.25	-0.93
Total Shareholders' Equity	1.71M	2.34M	18.91M	-18.59M	-90.45M	81.51M	8.91M	11.37M	-11.31M
Common Stock	612	612	94K	95K	156K	300K	3K	96K	110K
Retained Earnings	1.7M	2.34M	-39.8M	-80.45M	-160.56M	-215.13M	-107.01M	-142.2M	-194.1M
Treasury Stock	0	0	-1.52M	-1.81M	-1.85M	0	0	-150K	-150K
Accumulated OCI	0	0	0	0	-333K	-103K	0	-197K	-175K
Minority Interest	2.53M	2.12M	0	0	0	0	0	0	0

Cash Flow

	Dec 2012	Dec 2013	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.07M	1.89M	-8.02M	-24.59M	-22.89M	-23.94M	-22.18M	-32.69M	-37.07M
Operating CF Margin %	0.15%	0.29%	-1.99%	-16.54%	-7.95%	-0.85%	-	-	-
Operating CF Growth %	-	0.78%	-5.24%	-2.07%	0.07%	-0.05%	0.07%	-0.47%	-0.13%
Net Income	307.3K	632.24K	-20.02M	-40.66M	-80.11M	-26.4M	-28.21M	-35.2M	-51.9M
Depreciation & Amortization	463.22K	460.34K	2K	496K	628K	251.45K	1.06M	1.17M	1.18M
Stock-Based Compensation	0	0	0	0	0	617.76K	579K	1.18M	1.45M
Deferred Taxes	-212K	-118K	0	0	0	52.96K	0	0	0
Other Non-Cash Items	1.18M	1.58M	8.29M	5.82M	30.82M	667.05K	4.54M	209K	8.24M
Working Capital Changes	-74.98K	332.64K	3.09M	9.75M	25.77M	872.43K	-150K	-57K	3.96M
Change in Receivables	224.91K	94.62K	180K	-333K	440K	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	103.5K	-171.89K	449K	-118K	-5.61M	30.23K	1.13M	23K	-3.33M
Cash from Investing+	-47.73K	-67.58K	0	-242K	-41K	-525.36K	-654K	-32K	-84K
Capital Expenditures	-47.73K	-17.57K	0	-242K	-41K	-525.36K	-654K	-66K	-87K
CapEx % of Revenue	0.01%	0%	-	0.16%	0.01%	0.02%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	34K	3K
Cash from Financing+	-429.23K	-1.17M	31.74M	4.89M	52.41M	19.39M	21.2M	38.61M	42.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-429.23K	-1.17M	0	0	0	314.88K	82K	21.76M	16.96M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.02M	1.87M	-8.02M	-24.83M	-22.93M	-24.46M	-22.83M	-32.76M	-37.16M
FCF Margin %	0.14%	0.28%	-1.99%	-16.7%	-7.96%	-0.86%	-	-	-
FCF Growth %	-	0.84%	-5.28%	-2.1%	0.08%	-0.07%	0.07%	-0.43%	-0.13%
FCF per Share	166.25	306.33	-2.72	-3.05	-2.81	-7.65	-7.37	-6.48	-3.04
FCF Conversion (FCF/Net Income)	3.47x	2.99x	0.40x	0.60x	0.29x	0.91x	0.79x	0.93x	0.71x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2012	2013	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.25%	14.54%	-171.37%	-25020.31%	-	-32.39%	-62.39%	-346.95%	-170157.38%
Return on Invested Capital (ROIC)	-3.8%	-3.73%	-1910.8%	-	-	-	-592.14%	-383.12%	-2692.7%
Gross Margin	49.66%	51.78%	90.57%	23.6%	36.88%	95.64%	-	-	-
Net Margin	4.21%	9.61%	-497.02%	-2734.23%	-2781.49%	-93.25%	-	-	-
Debt / Equity	1.28x	1.19x	-	-	-	0.06x	0.84x	0.61x	-
Interest Coverage	-1.36x	-1.32x	-	-	-6.25x	-44.85x	-6.60x	-33.75x	-98.87x
FCF Conversion	3.47x	2.99x	0.40x	0.60x	0.29x	0.91x	0.79x	0.93x	0.71x
Revenue Growth	-	-9.82%	-38.78%	-63.09%	93.68%	883.06%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Elicio Therapeutics, Inc. (ELTX) grew revenue by 0.0% over the past year. Growth has been modest.

Elicio Therapeutics, Inc. (ELTX) reported a net loss of $45.9M for fiscal year 2024.

Dividend & Returns

Elicio Therapeutics, Inc. (ELTX) has a return on equity (ROE) of -170157.4%. Negative ROE indicates the company is unprofitable.

Elicio Therapeutics, Inc. (ELTX) had negative free cash flow of $38.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Elicio Therapeutics, Inc. (ELTX) 10-Year Financial Performance & Capital Metrics

ELTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$44M -26.7%
Net Income -$52M -47.5%
EPS (Diluted) -4.25 +38.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -170157.38% -48943.2%
ROIC -2692.7% -602.8%
Debt/Equity -
Interest Coverage -98.87 -192.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM2.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.19%

ROCE

10Y Avg-328.74%

5Y Avg-209.92%

3Y Avg-175.56%

Latest-264.27%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2012	Dec 2013	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.3M	6.58M	4.03M	1.49M	2.88M	28.31M	0	0	0
Revenue Growth %	-	-0.1%	-0.39%	-0.63%	0.94%	8.83%	-1%	-	-
Cost of Goods Sold+	3.67M	3.17M	380K	1.14M	1.82M	1.23M	1.06M	1.17M	1.18M
COGS % of Revenue	0.5%	0.48%	0.09%	0.76%	0.63%	0.04%	-	-	-
Gross Profit+	3.62M	3.41M	3.65M	351K	1.06M	27.08M	-1.06M	-1.17M	-1.18M
Gross Margin %	0.5%	0.52%	0.91%	0.24%	0.37%	0.96%	-	-	-
Gross Profit Growth %	-	-0.06%	0.07%	-0.9%	2.03%	24.5%	-1.04%	-0.11%	-0.01%
Operating Expenses+	4.04M	3.81M	17.99M	38.94M	56.34M	66.39M	22.68M	34.58M	43.81M
OpEx % of Revenue	0.55%	0.58%	4.47%	26.19%	19.56%	2.34%	-	-	-
Selling, General & Admin	4.04M	3.61M	8.84M	9.15M	17.46M	17.78M	5.63M	11.9M	11.33M
SG&A % of Revenue	0.55%	0.55%	2.19%	6.16%	6.06%	0.63%	-	-	-
Research & Development	0	196.01K	9.15M	29.79M	38.88M	48.61M	17.05M	22.68M	33.66M
R&D % of Revenue	-	0.03%	2.27%	20.03%	13.5%	1.72%	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	-1.18M
Operating Income+	-419.22K	-397.8K	-14.34M	-38.59M	-55.27M	-39.31M	-23.73M	-35.74M	-44.99M
Operating Margin %	-0.06%	-0.06%	-3.56%	-25.95%	-19.19%	-1.39%	-	-	-
Operating Income Growth %	-	0.05%	-35.05%	-1.69%	-0.43%	0.29%	0.4%	-0.51%	-0.26%
EBITDA+	44K	62.54K	-14.34M	-38.09M	-54.65M	-38.51M	-22.68M	-34.58M	-43.81M
EBITDA Margin %	0.01%	0.01%	-3.56%	-25.62%	-18.97%	-1.36%	-	-	-
EBITDA Growth %	-	0.42%	-230.28%	-1.66%	-0.43%	0.3%	0.41%	-0.52%	-0.27%
D&A (Non-Cash Add-back)	463.22K	460.34K	2K	496K	628K	801K	1.06M	1.17M	1.18M
EBIT	1.5M	2.03M	-20.02M	-40.66M	-71.26M	-52.73M	-24.61M	-34.14M	-51.44M
Net Interest Income+	0	0	0	81.48K	-8.85M	-873.05K	-3.53M	-686K	322K
Interest Income	0	0	252K	81.48K	0	3.39K	64.83K	373K	777K
Interest Expense	307.45K	300.43K	0	0	8.85M	876.44K	3.6M	1.06M	455K
Other Income/Expense	1.61M	2.13M	-5.68M	-2.07M	-24.83M	-15.27M	-4.47M	550K	-6.91M
Pretax Income+	1.19M	1.73M	-20.02M	-40.66M	-80.11M	-54.57M	-28.21M	-35.2M	-51.9M
Pretax Margin %	0.16%	0.26%	-4.97%	-27.34%	-27.81%	-1.93%	-	-	-
Income Tax+	201.86K	452.78K	0	0	0	0	0	0	0
Effective Tax Rate %	0.26%	0.36%	1%	1%	1%	0.48%	1%	1%	1%
Net Income+	307.3K	632.24K	-20.02M	-40.66M	-80.11M	-26.4M	-28.21M	-35.2M	-51.9M
Net Margin %	0.04%	0.1%	-4.97%	-27.34%	-27.81%	-0.93%	-	-	-
Net Income Growth %	-	1.06%	-32.67%	-1.03%	-0.97%	0.67%	-0.07%	-0.25%	-0.47%
Net Income (Continuing)	992.12K	1.28M	-20.02M	-40.66M	-80.11M	-54.57M	-28.21M	-35.2M	-51.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	2.53M	2.12M	0	0	0	0	0	0	0
EPS (Diluted)+	50.21	103.31	-6.79	-1.50	-1.93	-19.32	-9.10	-6.96	-4.25
EPS Growth %	-	1.06%	-1.07%	0.78%	-0.29%	-9.01%	0.53%	0.24%	0.39%
EPS (Basic)	50.21	103.31	-6.79	-1.50	-1.93	-19.32	-9.10	-6.96	-4.25
Diluted Shares Outstanding	6.12K	6.12K	2.95M	8.15M	8.15M	3.2M	3.1M	5.06M	12.2M
Basic Shares Outstanding	6.12K	6.12K	2.95M	8.15M	8.15M	3.2M	3.1M	5.06M	12.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2012	Dec 2013	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.06M	2.62M	25.68M	6.11M	40.32M	91.25M	10.72M	16.35M	20.69M
Cash & Short-Term Investments	1.4M	2.06M	25.51M	5.57M	34.61M	88.76M	7.8M	12.89M	17.62M
Cash Only	1.4M	2.06M	25.51M	5.57M	34.61M	88.76M	7.8M	12.89M	17.62M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	580.38K	485.76K	107K	440K	5M	806K	0	0	0
Days Sales Outstanding	29.03	26.94	9.69	108	633.68	10.39	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	60K	95K	360K	379K	36K	895K	1.28M
Total Non-Current Assets+	8.97M	8.44M	949K	5.78M	7.03M	5.27M	11.95M	10.8M	7.49M
Property, Plant & Equipment	6.61M	6.17M	17K	4.78M	4.23M	4.44M	8.5M	7.28M	6.19M
Fixed Asset Turnover	1.10x	1.07x	237.00x	0.31x	0.68x	6.38x	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	1.63M	1.67M	932K	999K	822K	723K	617K	0	696K
Other Non-Current Assets	734.38K	598.84K	0	0	1.98M	106K	2.83M	3.52M	600K
Total Assets+	11.03M	11.06M	26.63M	11.89M	47.35M	96.51M	22.66M	27.15M	28.18M
Asset Turnover	0.66x	0.59x	0.15x	0.13x	0.06x	0.29x	-	-	-
Asset Growth %	-	0%	1.41%	-0.55%	2.98%	1.04%	-0.77%	0.2%	0.04%
Total Current Liabilities+	1.1M	1.15M	7.36M	26.57M	107.45M	11.3M	6.87M	9.76M	11.52M
Accounts Payable	209.52K	37.62K	534K	11.24M	5.58M	4.71M	2.81M	4.37M	1.04M
Days Payables Outstanding	20.82	4.33	512.92	3.61K	1.12K	1.39K	968.61	1.36K	321.62
Short-Term Debt	115.58K	122.18K	0	6.88M	80.56M	952K	692K	0	901K
Deferred Revenue (Current)	91K	82K	19K	0	1000K	1000K	1000K	0	1000K
Other Current Liabilities	688.33K	905.11K	6.8M	6.35M	14.21M	3.33M	444K	2.57M	2.31M
Current Ratio	1.87x	2.28x	3.49x	0.23x	0.38x	8.08x	1.56x	1.68x	1.80x
Quick Ratio	1.87x	2.28x	3.49x	0.23x	0.38x	8.08x	1.56x	1.68x	1.80x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.69M	5.46M	362K	3.9M	30.35M	3.71M	6.88M	6.02M	27.97M
Long-Term Debt	5.32M	5.2M	0	0	635K	0	0	0	20.03M
Capital Lease Obligations	0	0	0	3.9M	3.85M	3.71M	6.79M	6.01M	5.11M
Deferred Tax Liabilities	113K	4K	0	0	0	0	0	0	0
Other Non-Current Liabilities	250K	250K	0	0	0	0	92K	11K	2.83M
Total Liabilities	6.79M	6.6M	7.72M	30.47M	137.8M	15.01M	13.75M	15.77M	39.49M
Total Debt+	5.44M	5.32M	0	10.78M	85.04M	4.66M	7.48M	6.92M	26.04M
Net Debt	4.04M	3.27M	-25.51M	5.21M	50.44M	-84.09M	-316K	-5.98M	8.42M
Debt / Equity	1.28x	1.19x	-	-	-	0.06x	0.84x	0.61x	-
Debt / EBITDA	123.65x	85.13x	-	-	-	-	-	-	-
Net Debt / EBITDA	91.73x	52.24x	-	-	-	-	-	-	-
Interest Coverage	-1.36x	-1.32x	-	-	-6.25x	-44.85x	-6.60x	-33.75x	-98.87x
Total Equity+	4.24M	4.46M	18.91M	-18.59M	-90.45M	81.51M	8.91M	11.37M	-11.31M
Equity Growth %	-	0.05%	3.24%	-1.98%	-3.87%	1.9%	-0.89%	0.28%	-1.99%
Book Value per Share	692.52	728.69	6.41	-2.28	-11.10	25.47	2.88	2.25	-0.93
Total Shareholders' Equity	1.71M	2.34M	18.91M	-18.59M	-90.45M	81.51M	8.91M	11.37M	-11.31M
Common Stock	612	612	94K	95K	156K	300K	3K	96K	110K
Retained Earnings	1.7M	2.34M	-39.8M	-80.45M	-160.56M	-215.13M	-107.01M	-142.2M	-194.1M
Treasury Stock	0	0	-1.52M	-1.81M	-1.85M	0	0	-150K	-150K
Accumulated OCI	0	0	0	0	-333K	-103K	0	-197K	-175K
Minority Interest	2.53M	2.12M	0	0	0	0	0	0	0

Cash Flow

	Dec 2012	Dec 2013	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.07M	1.89M	-8.02M	-24.59M	-22.89M	-23.94M	-22.18M	-32.69M	-37.07M
Operating CF Margin %	0.15%	0.29%	-1.99%	-16.54%	-7.95%	-0.85%	-	-	-
Operating CF Growth %	-	0.78%	-5.24%	-2.07%	0.07%	-0.05%	0.07%	-0.47%	-0.13%
Net Income	307.3K	632.24K	-20.02M	-40.66M	-80.11M	-26.4M	-28.21M	-35.2M	-51.9M
Depreciation & Amortization	463.22K	460.34K	2K	496K	628K	251.45K	1.06M	1.17M	1.18M
Stock-Based Compensation	0	0	0	0	0	617.76K	579K	1.18M	1.45M
Deferred Taxes	-212K	-118K	0	0	0	52.96K	0	0	0
Other Non-Cash Items	1.18M	1.58M	8.29M	5.82M	30.82M	667.05K	4.54M	209K	8.24M
Working Capital Changes	-74.98K	332.64K	3.09M	9.75M	25.77M	872.43K	-150K	-57K	3.96M
Change in Receivables	224.91K	94.62K	180K	-333K	440K	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	103.5K	-171.89K	449K	-118K	-5.61M	30.23K	1.13M	23K	-3.33M
Cash from Investing+	-47.73K	-67.58K	0	-242K	-41K	-525.36K	-654K	-32K	-84K
Capital Expenditures	-47.73K	-17.57K	0	-242K	-41K	-525.36K	-654K	-66K	-87K
CapEx % of Revenue	0.01%	0%	-	0.16%	0.01%	0.02%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	34K	3K
Cash from Financing+	-429.23K	-1.17M	31.74M	4.89M	52.41M	19.39M	21.2M	38.61M	42.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-429.23K	-1.17M	0	0	0	314.88K	82K	21.76M	16.96M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.02M	1.87M	-8.02M	-24.83M	-22.93M	-24.46M	-22.83M	-32.76M	-37.16M
FCF Margin %	0.14%	0.28%	-1.99%	-16.7%	-7.96%	-0.86%	-	-	-
FCF Growth %	-	0.84%	-5.28%	-2.1%	0.08%	-0.07%	0.07%	-0.43%	-0.13%
FCF per Share	166.25	306.33	-2.72	-3.05	-2.81	-7.65	-7.37	-6.48	-3.04
FCF Conversion (FCF/Net Income)	3.47x	2.99x	0.40x	0.60x	0.29x	0.91x	0.79x	0.93x	0.71x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2012	2013	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.25%	14.54%	-171.37%	-25020.31%	-	-32.39%	-62.39%	-346.95%	-170157.38%
Return on Invested Capital (ROIC)	-3.8%	-3.73%	-1910.8%	-	-	-	-592.14%	-383.12%	-2692.7%
Gross Margin	49.66%	51.78%	90.57%	23.6%	36.88%	95.64%	-	-	-
Net Margin	4.21%	9.61%	-497.02%	-2734.23%	-2781.49%	-93.25%	-	-	-
Debt / Equity	1.28x	1.19x	-	-	-	0.06x	0.84x	0.61x	-
Interest Coverage	-1.36x	-1.32x	-	-	-6.25x	-44.85x	-6.60x	-33.75x	-98.87x
FCF Conversion	3.47x	2.99x	0.40x	0.60x	0.29x	0.91x	0.79x	0.93x	0.71x
Revenue Growth	-	-9.82%	-38.78%	-63.09%	93.68%	883.06%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Elicio Therapeutics, Inc. (ELTX) grew revenue by 0.0% over the past year. Growth has been modest.

Elicio Therapeutics, Inc. (ELTX) reported a net loss of $45.9M for fiscal year 2024.

Dividend & Returns

Elicio Therapeutics, Inc. (ELTX) has a return on equity (ROE) of -170157.4%. Negative ROE indicates the company is unprofitable.

Elicio Therapeutics, Inc. (ELTX) had negative free cash flow of $38.9M in fiscal year 2024, likely due to heavy capital investments.